Table 4 Use of anti-osteoporosis drugs in the BMD <70 % of YAM and BMD ≥70 % of YAM groups
From: Risk of low bone mineral density in patients with rheumatoid arthritis treated with biologics
|  | BMD <70 % of YAM | BMD ≥70 % of YAM |
|---|---|---|
None | 13 | 58 |
Anti-osteoporosis drug use (total) | 44 | 71 |